Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model

about

Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model

Item

http://www.wikidata.org/entity/Q58027781

description

scientific article published on 22 August 2018

@en

наукова стаття, опублікована у квітні 2018

@uk

name

Developing new health technolo ...... ortfolio review and cost model

@en

type

Item

label

Developing new health technolo ...... ortfolio review and cost model

@en

prefLabel

Developing new health technolo ...... ortfolio review and cost model

@en

P1476

Developing new health technolo ...... ortfolio review and cost model

@en

P2093

Bill Rodriguez

http://www.w3.org/2001/XMLSchema#string

Johan Persson

http://www.w3.org/2001/XMLSchema#string

Kelsey Corrigan

http://www.w3.org/2001/XMLSchema#string

Marco Schäferhoff

http://www.w3.org/2001/XMLSchema#string

Sallie Permar

http://www.w3.org/2001/XMLSchema#string

Sebastián Martinez

http://www.w3.org/2001/XMLSchema#string

Tulika Singh

http://www.w3.org/2001/XMLSchema#string

Vipul Chowdhary

http://www.w3.org/2001/XMLSchema#string

P2860

Global health 2035: a world converging within a generation

Achieving a "Grand Convergence" in Global Health: Modeling the Technical Inputs, Costs, and Impacts from 2016 to 2030.

Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes.

Clinical development success rates for investigational drugs.

Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis

Why has under-5 mortality decreased at such different rates in different countries?

The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions.

Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: an assessment of the feasibility of post-2015 goals.

Innovation in the pharmaceutical industry: New estimates of R&D costs.

Retrospective cost-effectiveness analyses for polio vaccination in the United States.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/GATESOPENRES.12817.1

http://www.w3.org/2001/XMLSchema#string

10.12688/GATESOPENRES.12817.3

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30234193

http://www.w3.org/2001/XMLSchema#string

P921

Neglected diseases

Financing

P932

6139384

http://www.w3.org/2001/XMLSchema#string